Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:EDSA NASDAQ:INKT NASDAQ:IZTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.38-6.3%$0.55$0.30▼$3.42$15.29M-1.8846,546 shs1,762 shsEDSAEdesa Biotech$5.46-23.0%$9.16$0.72▼$20.32$63.04M1.03314,939 shs764,215 shsINKTMiNK Therapeutics$11.87-6.9%$11.41$6.80▼$76.00$63.52M0.4744,063 shs51,453 shsIZTCInvizyne Technologies$9.35-1.2%$9.76$8.50▼$23.00$58.46MN/A37,647 shs7,340 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+6.64%-3.80%-13.04%-12.09%-61.90%EDSAEdesa Biotech+3.35%-9.80%-54.11%+8.74%+263.59%INKTMiNK Therapeutics-0.08%+4.51%+10.49%+24.03%+79.58%IZTCInvizyne Technologies-0.42%-4.54%-2.97%+25.71%-29.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.38-6.3%$0.55$0.30▼$3.42$15.29M-1.8846,546 shs1,762 shsEDSAEdesa Biotech$5.46-23.0%$9.16$0.72▼$20.32$63.04M1.03314,939 shs764,215 shsINKTMiNK Therapeutics$11.87-6.9%$11.41$6.80▼$76.00$63.52M0.4744,063 shs51,453 shsIZTCInvizyne Technologies$9.35-1.2%$9.76$8.50▼$23.00$58.46MN/A37,647 shs7,340 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+6.64%-3.80%-13.04%-12.09%-61.90%EDSAEdesa Biotech+3.35%-9.80%-54.11%+8.74%+263.59%INKTMiNK Therapeutics-0.08%+4.51%+10.49%+24.03%+79.58%IZTCInvizyne Technologies-0.42%-4.54%-2.97%+25.71%-29.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 1.50ReduceN/AN/AEDSAEdesa Biotech 2.00Hold$5.00-8.42% DownsideINKTMiNK Therapeutics 2.40Hold$35.00194.86% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ANEB, EDSA, INKT, and IZTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.005/12/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/1/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.003/27/2026EDSAEdesa Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/AEDSAEdesa BiotechN/AN/AN/AN/A$0.45 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($3.03) per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%N/AEDSAEdesa Biotech-$7.19M-$1.34N/AN/AN/AN/A-286.52%-75.36%8/14/2026 (Estimated)INKTMiNK Therapeutics-$12.49M-$2.84N/AN/AN/AN/AN/A-118.57%8/13/2026 (Estimated)IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest ANEB, EDSA, INKT, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026INKTMiNK Therapeutics-$0.77-$0.57+$0.20-$0.57N/AN/A5/14/2026Q2 2026EDSAEdesa Biotech-$0.24-$0.49-$0.25-$0.49$0.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A6.246.24EDSAEdesa BiotechN/A4.764.76INKTMiNK TherapeuticsN/A1.381.38IZTCInvizyne TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%EDSAEdesa Biotech5.50%INKTMiNK Therapeutics2.87%IZTCInvizyne TechnologiesN/AInsider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%EDSAEdesa Biotech24.40%INKTMiNK Therapeutics22.48%IZTCInvizyne TechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals440.79 million7.91 millionNot OptionableEDSAEdesa Biotech208.89 million6.72 millionNot OptionableINKTMiNK Therapeutics304.98 million3.86 millionNo DataIZTCInvizyne Technologies296.25 millionN/AN/AANEB, EDSA, INKT, and IZTC HeadlinesRecent News About These CompaniesInvizyne Technologies (NASDAQ:IZTC) Shares Up 5.5% - Should You Buy?May 27, 2026 | americanbankingnews.comInstitutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC)February 13, 2025 | uk.finance.yahoo.comWhat’s in a Name: Out with Invizyne, In with eXoZymesFebruary 12, 2025 | genengnews.comGInvizyne Technologies rebrands as eXoZymes with new ticker EXOZFebruary 11, 2025 | msn.comInvizyne announces corporate name change to eXoZymesFebruary 11, 2025 | markets.businessinsider.comWhy Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 12.35%February 4, 2025 | aaii.comAWhy Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 10.33%January 30, 2025 | aaii.comAInvizyne technologies CEO Michael Heltzen buys $20,345 in stockJanuary 21, 2025 | msn.comInvizyne Technologies Inc trading resumesJanuary 1, 2025 | markets.businessinsider.comInvizyne Technologies Inc trading halted, volatility trading pauseJanuary 1, 2025 | markets.businessinsider.comMichael Heltzen Buys 1,984 Shares of Invizyne Technologies Inc. (NASDAQ:IZTC) StockNovember 20, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANEB, EDSA, INKT, and IZTC Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$0.38 -0.03 (-6.25%) As of 02:21 PM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Edesa Biotech NASDAQ:EDSA$5.46 -1.63 (-22.99%) Closing price 04:00 PM EasternExtended Trading$5.52 +0.05 (+1.01%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.MiNK Therapeutics NASDAQ:INKT$11.87 -0.88 (-6.90%) Closing price 04:00 PM EasternExtended Trading$11.23 -0.64 (-5.39%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Invizyne Technologies NASDAQ:IZTC$9.35 -0.11 (-1.16%) As of 06/4/2026Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
